Trial Profile
Low Dose Treatment of Ribavirin in Combination With PEG-IFN Alfa-2b [Peginterferon alfa-2b] in CHC [chronic hepatitis C] Patients With genotype1 High Viral Load and Low Body Weight.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 13 Jan 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
- 13 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Dec 2009 Status changed from recruiting to active, no longer recruiting as reported by Clinicaltrials.gov.